Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

Cancer death rates in the UK have hit a record low, but the picture is more complicated than the headline figure suggests.

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...

Brian Holmes is the first man in the UK and the fifth in the world to receive the treatment.

Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is ...

The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.

Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours or halt their growth.

News, features, and commentary about cancer-related issues ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...